EXPANDED ACCESS POLICY

Revised November 18, 2019

VEANA THERAPEUTICS, Inc. (“VEANA”) is a clinical stage, research and development biotechnology company whose primary mission is to develop safer, more effective immunotherapies that will improve and extend the lives of the many people affected by the deadly disease of cancer. As part of the drug development process, VEANA conducts clinical trials to study the safety and efficacy of its investigational products. The information from these trials is used to support marketing applications submitted to FDA and other regulatory authorities.

Some drug companies may make their investigational drugs available to individual patients through an expanded access program. An expanded access program provides for the use of an investigational drug prior to approval by the FDA outside of the clinical trial setting.

We believe the best way to make our investigational drugs available to individuals is through their participation in one of our ongoing clinical trials.

For more information on VEANA’s clinical trials, see https://clinicaltrials.gov. Search for “VEANA” to find our clinical trials that may currently be recruiting.

If you are a healthcare professional and would like more information on VEANA’s investigational products, please contact info@veana-therapeutics.com.

We reserve the right to revise this policy at any time.

VEANA THERAPEUTICS, INC.
4640 SW Macadam, Suite 120, Portland, OR 97239, USA
info@veana-therapeutics.com